(June 22, 2023, 2:05 PM EDT) -- CHICAGO — The Seventh Circuit U.S. Court of Appeals ruled that the testosterone replacement therapy (TRT) multidistrict litigation court did not err in denying a new trial request over the late disclosure of a Food and Drug Administration letter about studying whether TRT drugs have a risk of high blood pressure, saying high blood pressure was only one of several causal factors in a trial where a man claimed that Androderm caused his heart attack....